Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2026-08-19 16:57:04 ET · period of report 2026-08-17 · accession 0001628280-26-058008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-08-19 16:57 | 2026-08-17 | ARQT | Welgus Howard G. | Dir | M - OptEx | $7.93 | +4,096 | 41.2K | +11% | +$32.5K |
| DT | 2026-08-19 16:57 | 2026-08-17 | ARQT | Welgus Howard G. | Dir | S - Sale+OE | $26.18 | -4,730 | 36.5K | -11% | -$123.8K |
| DMT | 2026-08-19 16:57 | 2026-08-17 | ARQT | Welgus Howard G. | Dir | M - OptEx | $0.00 | -4,096 | 20.3K | -17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-17 | M | A | 822 | $6.52 | 37,931 | D | — | — | (F1) The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. |
| 2 | Common | Common Stock | 2026-08-17 | M | A | 1,019 | $7.51 | 38,950 | D | — | — | (F1) The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. |
| 3 | Common | Common Stock | 2026-08-17 | M | A | 2,255 | $8.63 | 41,205 | D | — | — | (F1) The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. |
| 4 | Common | Common Stock | 2026-08-17 | S | D | 4,730 | $26.18 | 36,475 | D | — | — | (F1) The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.10 to $26.25 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 5 | Derivative | Stock Option (right to buy) | 2026-08-17 | M | D | 822 | $0.00 | 7,396 | D | $6.52 · — to 2029-11-20 | 822 Common Stock | (F1) The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. (F3) The option is fully vested. |
| 6 | Derivative | Stock Option (right to buy) | 2026-08-17 | M | D | 1,019 | $0.00 | 9,163 | D | $7.51 · — to 2033-05-31 | 1,019 Common Stock | (F1) The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027. (F3) The option is fully vested. |
| 7 | Derivative | Stock Option (right to buy) | 2026-08-17 | M | D | 2,255 | $0.00 | 20,287 | D | $8.63 · — to 2034-06-14 | 2,255 Common Stock | (F3) The option is fully vested. |